Feature | Heart Valve Technology | December 12, 2018

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation

Delaware court rules Edwards Lifesciences’ Sapien 3 aortic valve infringes Boston Scientific patent

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation

December 12, 2018 — A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S. patent 8,992,608 is valid and that Edwards Lifesciences' Sapien 3 Aortic Valve infringes this patent. The court ruled that Edwards owes Boston Scientific $35 million in infringement damages through the end of 2016. Additional damages and interest incurred from 2017-2018 will be determined by the court in post-trial motions.

The jury also found that the Boston Scientific Lotus Aortic Valve System does not infringe Edwards' Spenser patents U.S. 7,510,575, U.S. 9,168,133, or U.S. 9,339,383.

In a statement, Edwards said it does not expect to pay the jury award since “earlier this year, the U.S. Patent and Trademark office determined that all asserted claims of the '608 patent were invalid.” Edwards plans to appeal the jury’s ruling on the Spenser valve patents.

The Lotus system features an adaptive sealing technology, which creates an external seal to prevent leakage around the valve known as paravalvular leak (PVL), which is a proven predictor of mortality.i,ii,iii The company anticipates the Lotus Edge Valve System will be commercialized in CE mark countries in Q1 2019 and in the U.S. in mid-2019, pending U.S. Food and Drug Administration (FDA) regulatory approval timelines.

The Lotus valve is one of two valve systems in the Boston Scientific structural heart portfolio. Boston Scientific currently offers the Acurate neo Aortic Valve System in key European markets and is also seeking a CE mark application for the next-generation valve system, the Acurate neo2, which it intends to commercialize during the first half of 2019.

UPDATE: On Jan. 15, 2019, Edwards and Boston Scientific reached an agreement to settle all outstanding patent disputes between the companies in all venues around the world. All pending cases or appeals in courts and patent offices between the two companies will be dismissed, and the parties will not litigate patent disputes related to current portfolios of transcatheter aortic valves, certain mitral valve repair devices and left atrial appendage closure devices. Any injunctions currently in place will be lifted. 

Under the terms of the agreement, Edwards has made a one-time payment to Boston Scientific of $180 million. No further royalties will be owed by either party under the agreement. All other terms remained confidential. 

For more information: www.bostonscientific.com, www.edwards.com

 

References

i. Kodali S.K., et al. Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement. N Engl J Med 2012; 366:1686-1695

ii. Tamburino C., et al. Incidence and Predictors of Early and Late Mortality After Transcatheter Aortic Valve Implantation in 663 Patients With Severe Aortic Stenosis. Circ. 2011;123:299.

iii. Abdel-Wahab M., et al. Aortic Regurgitation After Transcatheter Aortic Valve Implantation: Incidence and Early Outcome. Results from the German Transcatheter Aortic Valve Implantation Registry. Heart 2011;97:899-906.

Related Content

Survey data showing opinions of physicians and hospital administrators on barriers to implementing new technology and how new technologies have improved cardiovascular care.

Survey data showing opinions of physicians and hospital administrators on barriers to implementing new technology and how new technologies have improved cardiovascular care.

News | Cardiovascular Business | September 14, 2020
September 14, 2020 — New global research released by Abbott takes a deep dive into the barriers of cardiovascular pat
Philips angiography system in a cath lab at Henry Ford Hospital.
Feature | Cardiovascular Business | July 13, 2020 | Deb Thompson and Christian Comeau
For a cardiovascular service line leader, addressing challenges in an evolving healthcare climate is a constant.
Leeds Hospital recently installed Philips Azurion angiography interventional labs to enhance procedural guidance capabilities.

Leeds Hospital recently installed Philips Azurion angiography interventional labs to enhance procedural guidance capabilities.

News | Cardiovascular Business | July 08, 2020
July 8, 2020 – Philips Healthcare and Leeds Teaching Hospitals NHS Trust announced a seven-year managed service agree
Medicare will pay for telehealth virtual doctor visits during the duration of the coronavirus COVID-19 outbreak.
News | Cardiovascular Business | March 17, 2020
March 17, 2020 — The Trump Administration today announced expanded Medicare telehealth coverage that will enable bene
Recognized as the “Pulitzer Prize of the business press,” the Jesse H. Neal Award finalists are selected for exhibiting journalistic enterprise, service to the industry and editorial craftsmanship
News | Cardiovascular Business | February 19, 2020
February 19, 2020 — Connectiv, a division of The Software and Information Industry Association (SIIA), has announced
 Cath Lab Philips Azurion angiography PCI
News | Cardiovascular Business | December 30, 2019
December 30, 2019 — Most patients do not understand or recall information given to them before heart procedures.
Siemens Healthineers Acquires ECG Management Consultants
News | Cardiovascular Business | November 11, 2019
November 11, 2019 — ECG Management Consultants, a leading U.S.